Get the Stockscreener App
1.50
2.60%
-0.04
Pre-market:
1.56
0.06
+4.00%
Geovax Labs Inc stock is traded at $1.50, with a volume of 38,544.
It is down -2.60% in the last 24 hours and down -9.64% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
See More
Previous Close:
$1.54
Open:
$1.58
24h Volume:
38,544
Relative Volume:
0.24
Market Cap:
$3.34M
Revenue:
$3.35M
Net Income/Loss:
$-25.31M
P/E Ratio:
-0.041
EPS:
-36.5794
Net Cash Flow:
$-24.29M
1W Performance:
+5.63%
1M Performance:
-9.64%
6M Performance:
-90.64%
1Y Performance:
-95.62%
1-Day Range:
$1.4801
$1.6252
1-Week Range:
$1.32
$1.6252
52-Week Range:
$1.26
$35.00
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1900 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.50 | 3.34M | 3.35M | -25.31M | -24.29M | -36.58 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
View All
Geovax Labs Inc Stock (GOVX) Latest News
GeoVax Advances Mpox and Smallpox Vaccine Toward Phase 3 Trial with Clinical Supply Milestone - citybuzz -
GeoVax Provides Update on GEO-MVA Program - Yahoo Finance
Ideas Watch: Is GeoVax Labs Inc Equity Warrants ROE strong enoughPortfolio Performance Summary & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
GeoVax Labs Inc expected to post a loss of $6.17 a shareEarnings Preview - TradingView
Certain Warrants of GeoVax Labs, Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2026. - marketscreener.com
If You Invested $1,000 in Geovax Labs Inc (GOVX) - Stock Titan
Published on: 2026-03-22 08:06:31 - baoquankhu1.vn
Loss Report: Does GeoVax Labs Inc Equity Warrant stock benefit from AI growth2026 Trading Recap & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Stock Analysis: Does GeoVax Labs Inc Equity Warrant align with a passive investing strategy2026 Closing Moves & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Short Squeeze: What is First Horizon Corporations debt to equity ratioProduct Launch & Daily Stock Trend Watchlist - baoquankhu1.vn
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
GeoVax Announces European Society of Medicine Publication Highlighting GEO-CM04S1 as a Next-Generation COVID-19 Vaccine for Immunocompromised Patients - Yahoo Finance
GeoVax Engages Global Health Organizations for Future Mpox/Smallpox Vaccine Procurement - citybuzz -
How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints - Yahoo Finance
GeoVax Initiates Outreach Regarding Future Procurement of GEO-MVA Mpox/Smallpox Vaccine - Yahoo Finance
GOVXW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Entry Recap: Can GeoVax Labs Inc. navigate macro headwinds2026 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Aug Decliners: Is GeoVax Labs Inc Equity Warrant benefiting from interest rate changes2025 Price Targets & Community Consensus Trade Signals - baoquankhu1.vn
Update Recap: Is GeoVax Labs Inc Equity Warrant gaining market share2025 Technical Patterns & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Aug Fed Impact: Is GeoVax Labs Inc Equity Warrant stock technically oversold2025 Breakouts & Breakdowns & Weekly Top Gainers Alerts - baoquankhu1.vn
GeoVax Labs Inc. (NASDAQ:GOVX) Sees Significant Decline in Short Interest - Defense World
Can POET Technologies Inc keep up with sector leaders2025 Price Targets & Long-Term Growth Portfolio Plans - baoquankhu1.vn
GOVX SEC FilingsGeovax Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GOVXW SEC FilingsGeovax Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Performance Recap: What is the long term forecast for GeoVax Labs Inc Equity Warrant stockJuly 2025 EndofMonth & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Insider Trends: Will GeoVax Labs Inc benefit from geopolitical trendsJuly 2025 Action & Risk Controlled Swing Alerts - baoquankhu1.vn
GOVX PE Ratio & Valuation, Is GOVX Overvalued - Intellectia AI
GOVX Should I Buy - Intellectia AI
GOVX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Hedge Fund Bets: What is Cross Country Healthcare Incs valuation compared to sectorGap Up & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Treasury Yields: Is GeoVax Labs Inc Equity Warrant a strong candidate for buy and holdInsider Buying & Advanced Technical Analysis Signals - baoquankhu1.vn
GeoVax Forms Oncology Advisory Board to Guide Gedeptin Development in Solid Tumors - citybuzz -
GeoVax Announces Oncology Advisory Board to Advance Gedeptin(R) Development Across Solid Tumors - Yahoo Finance
GOVX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Aug Final Week: Does GeoVax Labs Inc Equity Warrant align with a passive investing strategy2025 Fundamental Recap & Community Verified Trade Alerts - baoquankhu1.vn
GOVX Stock Price, Forecast & Analysis | GEOVAX LABS INC (NASDAQ:GOVX) - ChartMill
Bull Bear: What is the long term forecast for GeoVax Labs Inc Equity Warrant stockTake Profit & Weekly Return Optimization Alerts - baoquankhu1.vn
GeoVax Labs downgraded to Hold from Buy at D. Boral Capital - TipRanks
D. Boral Capital downgrades GeoVax Labs stock rating to Hold - Investing.com Nigeria
D. Boral Capital downgrades GeoVax Labs stock rating to Hold By Investing.com - Investing.com South Africa
Geovax Labs (GOVX) Receives Downgrade to 'Hold' by D. Boral Capi - GuruFocus
GeoVax Expands Immuno-Oncology Portfolio with Exclusive License for Gedeptin Combination Technology - citybuzz -
GeoVax Expands Immuno-Oncology Strategy with Exclusive License for Gedeptin Combination Technology - citybuzz -
GeoVax Secures Exclusive License for Gedeptin(R) + Immune Checkpoint Inhibitor Combination Technology - Yahoo Finance
Dow Update: Will GeoVax Labs Inc outperform the market in YEARJuly 2025 Setups & Reliable Breakout Forecasts - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
GeoVax Labs Announces Financing Through Equity Offerings - TipRanks
GeoVax Raises ~$0.87M at $2.31 in Registered Direct Offering, Adds Private Warrants - TradingView
GeoVax Endorses Global Call for Sustained Mpox Response, Highlights Vaccine Program Readiness - citybuzz -
GeoVax Endorses Global Call to Sustain Mpox Response as Evidence Confirms Epidemic Is Far From Over - TradingView
GeoVax Labs Inc. (NASDAQ:GOVX) Short Interest Update - Defense World
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):